Kalofonos Isabel
Chief Commercial Officer
Kalofonos Isabel has filed 3 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2026. 3 of those filings fall inside the rolling window. Most recent filing: Sep 1, 2026.
On the most recent filing, Kalofonos Isabel is listed as Chief Commercial Officer at Crinetics Pharmaceuticals, Inc. Inside the rolling window, Kalofonos Isabel reported no open-market purchases and 1 open-market sale totaling $138K in CRNX.
Companies traded
Other insiders at CRNX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$138K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kalofonos Isabel made?
Kalofonos Isabel has filed 3 SEC Form 4 filings (5 transaction rows) across 1 company since 2026.
Which companies does Kalofonos Isabel trade?
Kalofonos Isabel has filed SEC Form 4 disclosures for 1 company, including CRNX.
When was Kalofonos Isabel's most recent SEC Form 4 filing?
Kalofonos Isabel's most recent SEC Form 4 filing on Tracefour is dated Sep 1, 2026.
What is Kalofonos Isabel's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Kalofonos Isabel is listed as Chief Commercial Officer.
What is Kalofonos Isabel's total buy and sell value in the current window?
Inside the rolling retention window, Kalofonos Isabel bought $0 and sold $138K based on SEC Form 4 filings.
What was Kalofonos Isabel's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,500 CRNX shares on 2026-01-05, worth $138K, per SEC Form 4 filings.